Cabaletta bio to participate in guggenheim's smid cap biotech conference

Philadelphia, jan. 29, 2025 (globe newswire) -- cabaletta bio, inc. (nasdaq: caba), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the company will participate in a fireside chat at guggenheim's smid cap biotech conference on wednesday, february 5, 2025, at 10:30 a.m. et in new york, ny.
SMID Ratings Summary
SMID Quant Ranking